ArQule, Inc. Release: Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to be Presented a American Society of Clinical Oncology
Published: Jun 04, 2012
WOBURN, Mass. & TOKYO--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE: 4568) today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC). The data are to be presented today at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) (abstract number 4006).